Argenx
ARGX
#534
Rank
โ‚ฌ36.80 B
Marketcap
601,86ย โ‚ฌ
Share price
-0.35%
Change (1 day)
87.05%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2021 (TTM): โ‚ฌ0.19 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.79 Billion. In 2019 the company made a revenue of โ‚ฌ78.16 Million an increase over the revenue in the year 2018 that were of โ‚ฌ24.57 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2021

Annual revenue

Year Revenue Change
2021 (TTM) โ‚ฌ0.19 B
2019 โ‚ฌ78.16 M218.1%
2018 โ‚ฌ24.57 M-43.75%
2017 โ‚ฌ43.68 M182.33%
2016 โ‚ฌ15.47 M106.49%
2015 โ‚ฌ7.49 M64.07%
2014 โ‚ฌ4.56 M23.56%
2013 โ‚ฌ3.69 M